Isis Pharmaceuticals (ISIS) 72.02 $ISIS 'Mad Mo
Post# of 64200
Posted On: 03/16/2015 1:57:57 PM
Isis Pharmaceuticals (ISIS) 72.02 $ISIS
'Mad Money' Lightning Round: Buy, Buy, Buy MasterCard
at The Street - Fri Mar 13, 5:00AM CDT
Cramer prefers Regeneron over Novavzx and really likes LAM Research.
BMRN: 124.46 (+0.94), ISIS: 72.02 (+1.36), LRCX: 79.51 (+0.80), NVAX: 9.43 (+0.14), REGN: 447.92 (+18.54), MA: 88.60 (+0.85)
MasterCard Is At A Discount - Cramer's Lightning Round (3/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Mar 13, 4:16AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 12. Bullish Calls: Lam Research (NASDAQ: LRCX ): "It's really good! You have to be careful because there is a good chance someone will...
BMRN: 124.46 (+0.94), ISIS: 72.02 (+1.36), SGEN: 39.03 (+0.72), LRCX: 79.51 (+0.80), NVAX: 9.43 (+0.14), INTC: 30.79 (-0.14), MA: 88.60 (+0.85), REGN: 447.92 (+18.54)
Jim Cramer's 'Mad Money' Recap: Be Positive, Don't Be Complacent
at The Street - Thu Mar 12, 7:25PM CDT
Cramer says the markets are sailing along quite well in these uncertain times today, the 10th anniversary of 'Mad Money.'
BMRN: 124.46 (+0.94), ISIS: 72.02 (+1.36), LRCX: 79.51 (+0.80), NVAX: 9.43 (+0.14), CMG: 679.16 (+4.65), DIS: 107.44 (+1.00), INTC: 30.79 (-0.14), BA: 153.24 (+1.67), AAPL: 124.15 (+0.56), REGN: 447.92 (+18.54), MA: 88.60 (+0.85)
Can Isis Pharmaceuticals (ISIS) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 10, 7:46AM CDT
Isis Pharmaceuticals has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well.
ISIS: 72.02 (+1.36)
Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 2:30PM CDT
Isis Pharmaceuticals (ISIS) earned a milestone payment of $9 million from Biogen for advancing ISIS-SMNRx in infants suffering from spinal muscular atrophy.
BIIB: 420.71 (+7.36), ISIS: 72.02 (+1.36), GSK: 46.92 (+0.55), THRX: 17.16 (-0.41)
Isis Pharmaceuticals (ISIS) Upgraded From Sell to Hold
at The Street - Mon Mar 09, 12:20PM CDT
Isis Pharmaceuticals (ISIS) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.
ISIS: 72.02 (+1.36)
Interleukin Genetics Expands its Collaboration with Isis Pharmaceuticals for Genetic Testing Services
Business Wire - Mon Mar 09, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that under the terms of its collaboration agreement with Isis Pharmaceuticals, the Company will provide Isis with testing kits and will prepare DNA, run genotypes and provide data for SNP genotypes for the IL-1 and LP(a) SNPs for Isis' Phase 1 clinical study evaluating its novel therapeutic, ISIS-APO(a)-LRx in healthy volunteers with elevated lipoprotein(a), or Lp(a). Lp(a) is an independent risk factor for cardiovascular disease. This Phase I study is the second Isis clinical study to incorporate Interleukin's genetic test into the trial design to add genetic information at the earliest phases of testing of their new product lines.
ISIS: 72.02 (+1.36)
Isis Pharmaceuticals earns USD9m for progressing ISIS-SMN Rx into Phase 3 study in infants with spinal muscular atrophy
M2 - Mon Mar 09, 5:31AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) revealed on Friday that it has earned a USD9m milestone payment from Biogen Idec related to advancing the ongoing pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA) in the ENDEAR study.
BIIB: 420.71 (+7.36), ISIS: 72.02 (+1.36)
ISIS Pharmaceuticals Has The Cash To Develop Its Expanding Product Pipeline
Emerging Equities - at Seeking Alpha - Fri Mar 06, 4:03PM CST
BIIB: 420.71 (+7.36), ISIS: 72.02 (+1.36), IBB: 352.71 (+7.38), GSK: 46.92 (+0.55), ETF: 12.45 (unch)
Isis Pharma earns $9M milestone from Biogen
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:28AM CST
BIIB: 420.71 (+7.36), ISIS: 72.02 (+1.36)
It's All About Execution - Cramer's Mad Money (3/5/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Mar 06, 6:31AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, March 5. Cramer started the show by talking about the lost art of valuing execution. He is of the opinion that stocks run due to good leadership and perfect...
GPRO: 39.17 (-0.96), AMZN: 372.55 (+1.97), TSLA: 193.44 (+4.76), GD: 134.43 (+2.24), KR: 77.04 (+0.69), PCYC: 256.08 (+1.10), FB: 77.66 (-0.39), UTX: 119.62 (+0.88), NOC: 160.53 (+2.97), WMT: 83.14 (+1.24), LVS: 53.06 (+0.69), LPI: 11.06 (-0.12), BA: 153.24 (+1.67), GOOG: 555.72 (+8.40), NFLX: 419.31 (-19.09), ISIS: 72.02 (+1.36), TGT: 80.49 (+1.31), COST: 149.77 (+0.49), RCPT: 148.69 (-0.73), GOOGL: 562.74 (+9.74), ABBV: 58.86 (+0.86), OA: 76.60 (-0.23), CRM: 65.75 (+1.15)
Can The Uptrend Continue for ISIS Pharmaceuticals (ISIS)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 6:14AM CST
Can The Uptrend Continue for ISIS Pharmaceuticals (ISIS)?
ISIS: 72.02 (+1.36)
Jim Cramer's 'Mad Money' Recap: Why Aren't Well-Run Companies Getting Respect?
at The Street - Thu Mar 05, 7:27PM CST
Cramer says what seems overvalued on paper today might surprise you and be in a whole new category tomorrow.
BID: 40.98 (+0.45), TSLA: 193.44 (+4.76), GWRE: 52.09 (-0.14), ZIOP: 13.13 (-0.19), GE: 25.43 (+0.39), LMT: 200.95 (+3.84), PCYC: 256.08 (+1.10), BX: 38.31 (+0.36), BMRN: 124.46 (+0.94), UTX: 119.62 (+0.88), HZO: 26.51 (-0.12), XOM: 84.18 (+0.31), CZR: 9.49 (-0.06), SBUX: 94.03 (+0.74), ETP: 53.81 (-0.60), SSYS: 57.73 (-0.06), RCPT: 148.69 (-0.73), COST: 149.77 (+0.49), ABBV: 58.86 (+0.86), TRAK: 37.80 (+0.61), ROL: 23.56 (+0.44), OA: 76.60 (-0.23), MOV: 23.81 (-0.06), MBLY: 42.06 (+0.43), CSCO: 28.25 (+0.31), URI: 87.48 (-0.32), CTRL: 12.10 (-0.30), AMZN: 372.55 (+1.97), GPRO: 39.17 (-0.96), KR: 77.04 (+0.69), WFC: 55.58 (+0.24), NXPI: 104.07 (-0.60), BMY: 67.80 (+0.93), BA: 153.24 (+1.67), HPQ: 32.29 (-0.14), DRI: 64.37 (+1.27), ISIS: 72.02 (+1.36), MCD: 97.05 (+0.70), CVX: 102.56 (+0.94), BABA: 83.95 (+2.09)
Market Is Looking For Positive News - Cramer's Mad Money (3/4/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 05, 6:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, March 4. The market closed lower on Wednesday, but Cramer still thinks the market and stocks will go higher on any positive news. Citing Wayfair's (NYSE: W )...
HYH: 47.02 (+0.41), RH: 92.27 (-0.23), GPRO: 39.17 (-0.96), BIIB: 420.71 (+7.36), BMRN: 124.46 (+0.94), PCYC: 256.08 (+1.10), KMB: 106.44 (+0.65), LLTC: 47.32 (+0.52), BMY: 67.80 (+0.93), ALKS: 66.63 (+0.24), CHRS: 31.03 (+2.07), CELG: 120.42 (+2.69), W: 33.15 (+0.70), ISIS: 72.02 (+1.36), GILD: 101.15 (+1.54), LH: 125.11 (+1.38), MCD: 97.05 (+0.70), REGN: 447.92 (+18.54), BABA: 83.95 (+2.09)
Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield
at The Street - Wed Mar 04, 7:14PM CST
Investors have to pay attention to see what's really worth buying.
RH: 92.27 (-0.23), BIIB: 420.71 (+7.36), BMRN: 124.46 (+0.94), PCYC: 256.08 (+1.10), HON: 102.33 (+1.16), KMB: 106.45 (+0.66), RRD: 18.61 (-0.85), JNJ: 100.71 (+1.50), W: 33.15 (+0.70), SCTY: 47.35 (-1.04), CMG: 679.16 (+4.65), RCPT: 148.69 (-0.73), FL: 61.24 (-0.07), REGN: 447.92 (+18.54), HYH: 47.02 (+0.41), CY: 15.87 (-0.08), SWKS: 96.06 (+3.14), VFC: 72.96 (+0.03), NXPI: 104.07 (-0.60), ALKS: 66.63 (+0.24), CELG: 120.40 (+2.67), WWAV: 41.76 (unch), URBN: 44.53 (-0.30), HAIN: 63.15 (+0.25), FSLR: 59.33 (-1.27), GOGO: 20.26 (+0.15), ISIS: 72.02 (+1.36), GILD: 101.15 (+1.54), MCD: 97.05 (+0.70), STM: 9.70 (+0.49), DST: 105.90 (+1.02), BIG: 50.51 (+0.45), AVGO: 129.02 (+4.02)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 6.96 (-0.08), VRTX: 127.63 (+3.63), ISIS: 72.02 (+1.36), GILD: 101.15 (+1.54), AMGN: 161.78 (+7.52), ARNA: 4.75 (-0.06), CELG: 120.40 (+2.67)
Pfizer Inc. Has a Growth Problem -- Here Are 3 Ways to Change That
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 04, 7:02AM CST
Source: Pfizer, Facebook. Pfizer might be the largest pharmaceutical products company in the world by revenue, but it looks far from a force to be reckoned with at the moment. Pfizer's problems in a nutshell Like much of the big...
ISIS: 72.02 (+1.36), JAZZ: 178.92 (+3.83), AZN: 68.95 (+1.60), PFE: 34.41 (+0.41)
Downgrade Alert for Isis Pharmaceuticals (ISIS)
Comtex SmarTrend(R) - Tue Mar 03, 7:06AM CST
Isis Pharmaceuticals (NASDAQ:ISIS) was downgraded from Buy to Hold at Stifel today. The stock closed yesterday at $66.80 on volume of 3.3 million shares, above average daily volume of 3.0 million. Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company currently has various compounds in clinical trials for a variety of diseases such as Crohn's disease, psoriasis, asthma, and cancer. Isis' broad medical chemistry and biology research programs support efforts in both antisense and small molecule drug delivery.
ISIS: 72.02 (+1.36)
Thromboembolism Therapeutics Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Mar 03, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66bfv/thromboembolism) has announced the addition of the "Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Cereno Scientific AB - CSL Limited - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - C-3 - CSL-3F7 - edoxaban tosylate - Gammarin - GCC-2107 - ISIS-FXIRx - Lysimab - Protein for Thromboembolism and Blood Coagulation - REG-2 - rivaroxaban - semuloparin - Small Molecules to Inhibit HDAC for Thromboembolism - TAP-ANV - YG-001 For more information visit http://www.researchandmarkets.com/research/s6...boembolism
PTLA: 41.39 (+0.69), ISIS: 72.02 (+1.36), RGDO: 1.45 (-0.02)
Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2015 - 22 Companies & 81 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/dj7p3w/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Bioblast Pharma Ltd. - Cellular Biomedicine Group, Inc. - Cytokinetics, Inc. - F. Hoffmann-La Roche Ltd. - Genethon - Genzyme Corporation - GMP-Orphan SAS - Isis Pharmaceuticals, Inc. - Longevity Biotech, Inc - Neurodyn Inc. - Neurotune AG - Nexgenix Pharmaceuticals, LLC - Novartis AG - OrphageniX, Inc. - Paratek Pharmaceuticals, Inc. - Pfizer Inc. - PTC Therapeutics, Inc. - Retrophin Inc. - Sarepta Therapeutics, Inc. - Trophos SA - Vybion, Inc. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/dj...l_muscular
CYTK: 7.75 (-0.23), ISIS: 72.02 (+1.36), SRPT: 13.94 (-0.17), PFE: 34.41 (+0.41), RTRX: 14.80 (+0.04), PTCT: 73.36 (+0.09), PRTK: 30.34 (+0.97), CBMG: 40.79 (+1.23), NVS: 97.83 (+0.79)
'Mad Money' Lightning Round: Buy, Buy, Buy MasterCard
at The Street - Fri Mar 13, 5:00AM CDT
Cramer prefers Regeneron over Novavzx and really likes LAM Research.
BMRN: 124.46 (+0.94), ISIS: 72.02 (+1.36), LRCX: 79.51 (+0.80), NVAX: 9.43 (+0.14), REGN: 447.92 (+18.54), MA: 88.60 (+0.85)
MasterCard Is At A Discount - Cramer's Lightning Round (3/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Mar 13, 4:16AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, March 12. Bullish Calls: Lam Research (NASDAQ: LRCX ): "It's really good! You have to be careful because there is a good chance someone will...
BMRN: 124.46 (+0.94), ISIS: 72.02 (+1.36), SGEN: 39.03 (+0.72), LRCX: 79.51 (+0.80), NVAX: 9.43 (+0.14), INTC: 30.79 (-0.14), MA: 88.60 (+0.85), REGN: 447.92 (+18.54)
Jim Cramer's 'Mad Money' Recap: Be Positive, Don't Be Complacent
at The Street - Thu Mar 12, 7:25PM CDT
Cramer says the markets are sailing along quite well in these uncertain times today, the 10th anniversary of 'Mad Money.'
BMRN: 124.46 (+0.94), ISIS: 72.02 (+1.36), LRCX: 79.51 (+0.80), NVAX: 9.43 (+0.14), CMG: 679.16 (+4.65), DIS: 107.44 (+1.00), INTC: 30.79 (-0.14), BA: 153.24 (+1.67), AAPL: 124.15 (+0.56), REGN: 447.92 (+18.54), MA: 88.60 (+0.85)
Can Isis Pharmaceuticals (ISIS) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 10, 7:46AM CDT
Isis Pharmaceuticals has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well.
ISIS: 72.02 (+1.36)
Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 2:30PM CDT
Isis Pharmaceuticals (ISIS) earned a milestone payment of $9 million from Biogen for advancing ISIS-SMNRx in infants suffering from spinal muscular atrophy.
BIIB: 420.71 (+7.36), ISIS: 72.02 (+1.36), GSK: 46.92 (+0.55), THRX: 17.16 (-0.41)
Isis Pharmaceuticals (ISIS) Upgraded From Sell to Hold
at The Street - Mon Mar 09, 12:20PM CDT
Isis Pharmaceuticals (ISIS) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.
ISIS: 72.02 (+1.36)
Interleukin Genetics Expands its Collaboration with Isis Pharmaceuticals for Genetic Testing Services
Business Wire - Mon Mar 09, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that under the terms of its collaboration agreement with Isis Pharmaceuticals, the Company will provide Isis with testing kits and will prepare DNA, run genotypes and provide data for SNP genotypes for the IL-1 and LP(a) SNPs for Isis' Phase 1 clinical study evaluating its novel therapeutic, ISIS-APO(a)-LRx in healthy volunteers with elevated lipoprotein(a), or Lp(a). Lp(a) is an independent risk factor for cardiovascular disease. This Phase I study is the second Isis clinical study to incorporate Interleukin's genetic test into the trial design to add genetic information at the earliest phases of testing of their new product lines.
ISIS: 72.02 (+1.36)
Isis Pharmaceuticals earns USD9m for progressing ISIS-SMN Rx into Phase 3 study in infants with spinal muscular atrophy
M2 - Mon Mar 09, 5:31AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) revealed on Friday that it has earned a USD9m milestone payment from Biogen Idec related to advancing the ongoing pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA) in the ENDEAR study.
BIIB: 420.71 (+7.36), ISIS: 72.02 (+1.36)
ISIS Pharmaceuticals Has The Cash To Develop Its Expanding Product Pipeline
Emerging Equities - at Seeking Alpha - Fri Mar 06, 4:03PM CST
BIIB: 420.71 (+7.36), ISIS: 72.02 (+1.36), IBB: 352.71 (+7.38), GSK: 46.92 (+0.55), ETF: 12.45 (unch)
Isis Pharma earns $9M milestone from Biogen
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:28AM CST
BIIB: 420.71 (+7.36), ISIS: 72.02 (+1.36)
It's All About Execution - Cramer's Mad Money (3/5/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Mar 06, 6:31AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, March 5. Cramer started the show by talking about the lost art of valuing execution. He is of the opinion that stocks run due to good leadership and perfect...
GPRO: 39.17 (-0.96), AMZN: 372.55 (+1.97), TSLA: 193.44 (+4.76), GD: 134.43 (+2.24), KR: 77.04 (+0.69), PCYC: 256.08 (+1.10), FB: 77.66 (-0.39), UTX: 119.62 (+0.88), NOC: 160.53 (+2.97), WMT: 83.14 (+1.24), LVS: 53.06 (+0.69), LPI: 11.06 (-0.12), BA: 153.24 (+1.67), GOOG: 555.72 (+8.40), NFLX: 419.31 (-19.09), ISIS: 72.02 (+1.36), TGT: 80.49 (+1.31), COST: 149.77 (+0.49), RCPT: 148.69 (-0.73), GOOGL: 562.74 (+9.74), ABBV: 58.86 (+0.86), OA: 76.60 (-0.23), CRM: 65.75 (+1.15)
Can The Uptrend Continue for ISIS Pharmaceuticals (ISIS)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 6:14AM CST
Can The Uptrend Continue for ISIS Pharmaceuticals (ISIS)?
ISIS: 72.02 (+1.36)
Jim Cramer's 'Mad Money' Recap: Why Aren't Well-Run Companies Getting Respect?
at The Street - Thu Mar 05, 7:27PM CST
Cramer says what seems overvalued on paper today might surprise you and be in a whole new category tomorrow.
BID: 40.98 (+0.45), TSLA: 193.44 (+4.76), GWRE: 52.09 (-0.14), ZIOP: 13.13 (-0.19), GE: 25.43 (+0.39), LMT: 200.95 (+3.84), PCYC: 256.08 (+1.10), BX: 38.31 (+0.36), BMRN: 124.46 (+0.94), UTX: 119.62 (+0.88), HZO: 26.51 (-0.12), XOM: 84.18 (+0.31), CZR: 9.49 (-0.06), SBUX: 94.03 (+0.74), ETP: 53.81 (-0.60), SSYS: 57.73 (-0.06), RCPT: 148.69 (-0.73), COST: 149.77 (+0.49), ABBV: 58.86 (+0.86), TRAK: 37.80 (+0.61), ROL: 23.56 (+0.44), OA: 76.60 (-0.23), MOV: 23.81 (-0.06), MBLY: 42.06 (+0.43), CSCO: 28.25 (+0.31), URI: 87.48 (-0.32), CTRL: 12.10 (-0.30), AMZN: 372.55 (+1.97), GPRO: 39.17 (-0.96), KR: 77.04 (+0.69), WFC: 55.58 (+0.24), NXPI: 104.07 (-0.60), BMY: 67.80 (+0.93), BA: 153.24 (+1.67), HPQ: 32.29 (-0.14), DRI: 64.37 (+1.27), ISIS: 72.02 (+1.36), MCD: 97.05 (+0.70), CVX: 102.56 (+0.94), BABA: 83.95 (+2.09)
Market Is Looking For Positive News - Cramer's Mad Money (3/4/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 05, 6:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, March 4. The market closed lower on Wednesday, but Cramer still thinks the market and stocks will go higher on any positive news. Citing Wayfair's (NYSE: W )...
HYH: 47.02 (+0.41), RH: 92.27 (-0.23), GPRO: 39.17 (-0.96), BIIB: 420.71 (+7.36), BMRN: 124.46 (+0.94), PCYC: 256.08 (+1.10), KMB: 106.44 (+0.65), LLTC: 47.32 (+0.52), BMY: 67.80 (+0.93), ALKS: 66.63 (+0.24), CHRS: 31.03 (+2.07), CELG: 120.42 (+2.69), W: 33.15 (+0.70), ISIS: 72.02 (+1.36), GILD: 101.15 (+1.54), LH: 125.11 (+1.38), MCD: 97.05 (+0.70), REGN: 447.92 (+18.54), BABA: 83.95 (+2.09)
Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield
at The Street - Wed Mar 04, 7:14PM CST
Investors have to pay attention to see what's really worth buying.
RH: 92.27 (-0.23), BIIB: 420.71 (+7.36), BMRN: 124.46 (+0.94), PCYC: 256.08 (+1.10), HON: 102.33 (+1.16), KMB: 106.45 (+0.66), RRD: 18.61 (-0.85), JNJ: 100.71 (+1.50), W: 33.15 (+0.70), SCTY: 47.35 (-1.04), CMG: 679.16 (+4.65), RCPT: 148.69 (-0.73), FL: 61.24 (-0.07), REGN: 447.92 (+18.54), HYH: 47.02 (+0.41), CY: 15.87 (-0.08), SWKS: 96.06 (+3.14), VFC: 72.96 (+0.03), NXPI: 104.07 (-0.60), ALKS: 66.63 (+0.24), CELG: 120.40 (+2.67), WWAV: 41.76 (unch), URBN: 44.53 (-0.30), HAIN: 63.15 (+0.25), FSLR: 59.33 (-1.27), GOGO: 20.26 (+0.15), ISIS: 72.02 (+1.36), GILD: 101.15 (+1.54), MCD: 97.05 (+0.70), STM: 9.70 (+0.49), DST: 105.90 (+1.02), BIG: 50.51 (+0.45), AVGO: 129.02 (+4.02)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 6.96 (-0.08), VRTX: 127.63 (+3.63), ISIS: 72.02 (+1.36), GILD: 101.15 (+1.54), AMGN: 161.78 (+7.52), ARNA: 4.75 (-0.06), CELG: 120.40 (+2.67)
Pfizer Inc. Has a Growth Problem -- Here Are 3 Ways to Change That
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 04, 7:02AM CST
Source: Pfizer, Facebook. Pfizer might be the largest pharmaceutical products company in the world by revenue, but it looks far from a force to be reckoned with at the moment. Pfizer's problems in a nutshell Like much of the big...
ISIS: 72.02 (+1.36), JAZZ: 178.92 (+3.83), AZN: 68.95 (+1.60), PFE: 34.41 (+0.41)
Downgrade Alert for Isis Pharmaceuticals (ISIS)
Comtex SmarTrend(R) - Tue Mar 03, 7:06AM CST
Isis Pharmaceuticals (NASDAQ:ISIS) was downgraded from Buy to Hold at Stifel today. The stock closed yesterday at $66.80 on volume of 3.3 million shares, above average daily volume of 3.0 million. Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company currently has various compounds in clinical trials for a variety of diseases such as Crohn's disease, psoriasis, asthma, and cancer. Isis' broad medical chemistry and biology research programs support efforts in both antisense and small molecule drug delivery.
ISIS: 72.02 (+1.36)
Thromboembolism Therapeutics Pipeline Review 2015 - 10 Companies & 15 Drug Profiles
M2 - Tue Mar 03, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/s66bfv/thromboembolism) has announced the addition of the "Thromboembolism - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bayer AG - Cereno Scientific AB - CSL Limited - Daiichi Sankyo Company, Limited - Gamma Therapeutics, Inc. - Green Cross Corporation - Isis Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Regado Biosciences, Inc. - Sanofi Drug Profiles - betrixaban - C-3 - CSL-3F7 - edoxaban tosylate - Gammarin - GCC-2107 - ISIS-FXIRx - Lysimab - Protein for Thromboembolism and Blood Coagulation - REG-2 - rivaroxaban - semuloparin - Small Molecules to Inhibit HDAC for Thromboembolism - TAP-ANV - YG-001 For more information visit http://www.researchandmarkets.com/research/s6...boembolism
PTLA: 41.39 (+0.69), ISIS: 72.02 (+1.36), RGDO: 1.45 (-0.02)
Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Review 2015 - 22 Companies & 81 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/dj7p3w/spinal_muscular) has announced the addition of the "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Bioblast Pharma Ltd. - Cellular Biomedicine Group, Inc. - Cytokinetics, Inc. - F. Hoffmann-La Roche Ltd. - Genethon - Genzyme Corporation - GMP-Orphan SAS - Isis Pharmaceuticals, Inc. - Longevity Biotech, Inc - Neurodyn Inc. - Neurotune AG - Nexgenix Pharmaceuticals, LLC - Novartis AG - OrphageniX, Inc. - Paratek Pharmaceuticals, Inc. - Pfizer Inc. - PTC Therapeutics, Inc. - Retrophin Inc. - Sarepta Therapeutics, Inc. - Trophos SA - Vybion, Inc. - Zambon Company S.p.A. For more information visit http://www.researchandmarkets.com/research/dj...l_muscular
CYTK: 7.75 (-0.23), ISIS: 72.02 (+1.36), SRPT: 13.94 (-0.17), PFE: 34.41 (+0.41), RTRX: 14.80 (+0.04), PTCT: 73.36 (+0.09), PRTK: 30.34 (+0.97), CBMG: 40.79 (+1.23), NVS: 97.83 (+0.79)
(0)
(0)